PI3K-话题@MedSci - williamhill asia

#PI3K#

79篇内容 | 1842人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2191012, encodeId=8ea921910121a, content=<a href='/topic/show?id=f5885086f1' target=_blank style='color:#2F92EE;'>#COPD#</a> <a href='/topic/show?id=ecfa1423117' target=_blank style='color:#2F92EE;'>#PI3K#</a> <a href='/topic/show?id=7ba812e35f3' target=_blank style='color:#2F92EE;'>#NF-κB#</a> <a href='/topic/show?id=7ee51303e38' target=_blank style='color:#2F92EE;'>#Nrf2#</a> <a href='/topic/show?id=e1cf82352c7' target=_blank style='color:#2F92EE;'>#肺部炎症#</a> <a href='/topic/show?id=755011190e49' target=_blank style='color:#2F92EE;'>#定喘汤#</a>, objectTitle=J Ethnopharmacol：结合网络药理学和药理学研究探讨定喘汤抗慢性阻塞性肺疾病的潜在机制, objectType=article, longId=815918, objectId=554b81591869, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240304/1709539529932_5610093.jpg, objectUrl=/article/show_article.do?id=554b81591869, replyNumber=0, likeNumber=67, createdTime=2024-03-04, rootId=0, userName=williamhill asia 管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=554b81591869, moduleTitle=J Ethnopharmacol：结合网络药理学和药理学研究探讨定喘汤抗慢性阻塞性肺疾病的潜在机制, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=554b81591869)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1333256, encodeId=6a4d1333256d2, content=<a href='/topic/show?id=ecfa1423117' target=_blank style='color:#2F92EE;'>#PI3K#</a>, objectTitle=Front Pharmacol：琥珀安神汤通过激活PI3K/AKT通路促进创伤性脑损伤大鼠的骨折愈合, objectType=article, longId=739340, objectId=ee3fe39340dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ee3fe39340dd, replyNumber=0, likeNumber=63, createdTime=2022-09-16, rootId=0, userName=ms1292405679162969, userId=7bb22500091, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ee3fe39340dd, moduleTitle=Front Pharmacol：琥珀安神汤通过激活PI3K/AKT通路促进创伤性脑损伤大鼠的骨折愈合, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=ee3fe39340dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1333255, encodeId=5102133325520, content=<a href='/topic/show?id=ecfa1423117' target=_blank style='color:#2F92EE;'>#PI3K#</a>, objectTitle=FDA 关闭 PI3K 抑制剂单臂试验的大门，会给中国新药研发带来哪些启示？, objectType=article, longId=725783, objectId=0217e25783c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0217e25783c1, replyNumber=0, likeNumber=0, createdTime=2022-05-01, rootId=0, userName=ms1292405679162969, userId=7bb22500091, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0217e25783c1, moduleTitle=FDA 关闭 PI3K 抑制剂单臂试验的大门，会给中国新药研发带来哪些启示？, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=0217e25783c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1333254, encodeId=7bed1333254a8, content=<a href='/topic/show?id=ecfa1423117' target=_blank style='color:#2F92EE;'>#PI3K#</a>, objectTitle=Clin Cancer Res：首次人源性I期研究评估了PI3K/mTOR抑制剂GDC-0084在胶质瘤患者中的应用, objectType=article, longId=293008, objectId=928829300830, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=928829300830, replyNumber=0, likeNumber=57, createdTime=2021-12-30, rootId=0, userName=ms1292405679162969, userId=7bb22500091, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=928829300830, moduleTitle=Clin Cancer Res：首次人源性I期研究评估了PI3K/mTOR抑制剂GDC-0084在胶质瘤患者中的应用, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=928829300830)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1333253, encodeId=703513332536b, content=<a href='/topic/show?id=ecfa1423117' target=_blank style='color:#2F92EE;'>#PI3K#</a>, objectTitle=PI3K/Akt信号通路在胃癌干细胞中的表达及意义, objectType=article, longId=220683, objectId=a4a2220683dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a4a2220683dd, replyNumber=0, likeNumber=67, createdTime=2021-11-22, rootId=0, userName=ms1292405679162969, userId=7bb22500091, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a4a2220683dd, moduleTitle=PI3K/Akt信号通路在胃癌干细胞中的表达及意义, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=a4a2220683dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1333252, encodeId=e0e3133325234, content=<a href='/topic/show?id=ecfa1423117' target=_blank style='color:#2F92EE;'>#PI3K#</a>, objectTitle=Br J Pharmacol:丁酸盐通过增强肠道屏障功能和FFA2介导的PI3K/AKT/mTOR信号通路改善糖尿病肾病骨骼肌萎缩, objectType=article, longId=218682, objectId=875c218682b2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=875c218682b2, replyNumber=0, likeNumber=45, createdTime=2021-10-17, rootId=0, userName=ms1292405679162969, userId=7bb22500091, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=875c218682b2, moduleTitle=Br J Pharmacol:丁酸盐通过增强肠道屏障功能和FFA2介导的PI3K/AKT/mTOR信号通路改善糖尿病肾病骨骼肌萎缩, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=875c218682b2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1333251, encodeId=25591333251e2, content=<a href='/topic/show?id=ecfa1423117' target=_blank style='color:#2F92EE;'>#PI3K#</a>, objectTitle=Clin Cancer Res：PI3K/mTORC1/2双重抑制剂Gedatolisib联合卡铂和紫杉醇治疗晚期实体肿瘤, objectType=article, longId=215909, objectId=bd1421590942, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bd1421590942, replyNumber=0, likeNumber=119, createdTime=2021-08-19, rootId=0, userName=ms1292405679162969, userId=7bb22500091, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bd1421590942, moduleTitle=Clin Cancer Res：PI3K/mTORC1/2双重抑制剂Gedatolisib联合卡铂和紫杉醇治疗晚期实体肿瘤, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=bd1421590942)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1333250, encodeId=88f113332502b, content=<a href='/topic/show?id=ecfa1423117' target=_blank style='color:#2F92EE;'>#PI3K#</a>, objectTitle=Nat Rev Drug Discov：PI3K抑制剂即将迎来大爆发, objectType=article, longId=213099, objectId=5d892130997b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5d892130997b, replyNumber=0, likeNumber=72, createdTime=2021-06-25, rootId=0, userName=ms1292405679162969, userId=7bb22500091, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5d892130997b, moduleTitle=Nat Rev Drug Discov：PI3K抑制剂即将迎来大爆发, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=5d892130997b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1333249, encodeId=1f33133324965, content=<a href='/topic/show?id=ecfa1423117' target=_blank style='color:#2F92EE;'>#PI3K#</a>, objectTitle=Nat Commun：靶向PI3K/AKT的过度激活诱导慢性淋巴细胞白血病的细胞死亡, objectType=article, longId=212706, objectId=7958212e06d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7958212e06d6, replyNumber=0, likeNumber=61, createdTime=2021-06-15, rootId=0, userName=ms1292405679162969, userId=7bb22500091, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7958212e06d6, moduleTitle=Nat Commun：靶向PI3K/AKT的过度激活诱导慢性淋巴细胞白血病的细胞死亡, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=7958212e06d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1333248, encodeId=bd791333248dd, content=<a href='/topic/show?id=ecfa1423117' target=_blank style='color:#2F92EE;'>#PI3K#</a>, objectTitle=Clin Cancer Res：首次人源性I期研究评估了PI3K/mTOR抑制剂GDC-0084在胶质瘤患者中的应用, objectType=article, longId=209923, objectId=cb352099230f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cb352099230f, replyNumber=0, likeNumber=63, createdTime=2021-04-15, rootId=0, userName=ms1292405679162969, userId=7bb22500091, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cb352099230f, moduleTitle=Clin Cancer Res：首次人源性I期研究评估了PI3K/mTOR抑制剂GDC-0084在胶质瘤患者中的应用, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=cb352099230f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1333247, encodeId=4c37133324e6e, content=<a href='/topic/show?id=ecfa1423117' target=_blank style='color:#2F92EE;'>#PI3K#</a>, objectTitle=信达生物PI3Kδ抑制剂parsaclisib拟纳入突破性治疗品种, objectType=article, longId=208978, objectId=80682089e8c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=80682089e8c1, replyNumber=0, likeNumber=58, createdTime=2021-03-26, rootId=0, userName=ms1292405679162969, userId=7bb22500091, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=80682089e8c1, moduleTitle=信达生物PI3Kδ抑制剂parsaclisib拟纳入突破性治疗品种, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=80682089e8c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1333246, encodeId=719e133324607, content=<a href='/topic/show?id=ecfa1423117' target=_blank style='color:#2F92EE;'>#PI3K#</a>, objectTitle=Br J Cancer：PI3K信号通路激活导致HER2阴性乳腺癌的eribulin耐药性的产生, objectType=article, longId=208867, objectId=cb1020886ea9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cb1020886ea9, replyNumber=0, likeNumber=69, createdTime=2021-03-24, rootId=0, userName=ms1292405679162969, userId=7bb22500091, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cb1020886ea9, moduleTitle=Br J Cancer：PI3K信号通路激活导致HER2阴性乳腺癌的eribulin耐药性的产生, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=cb1020886ea9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1333245, encodeId=88e2133324591, content=<a href='/topic/show?id=ecfa1423117' target=_blank style='color:#2F92EE;'>#PI3K#</a>, objectTitle=J Clin Oncol：PI3Kδ/CK1ε双重抑制剂Umbralisib用于治疗复发性/难治性惰性淋巴瘤, objectType=article, longId=208223, objectId=84b3208223f8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=84b3208223f8, replyNumber=0, likeNumber=62, createdTime=2021-03-11, rootId=0, userName=ms1292405679162969, userId=7bb22500091, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=84b3208223f8, moduleTitle=J Clin Oncol：PI3Kδ/CK1ε双重抑制剂Umbralisib用于治疗复发性/难治性惰性淋巴瘤, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=84b3208223f8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1333244, encodeId=e196133324462, content=<a href='/topic/show?id=ecfa1423117' target=_blank style='color:#2F92EE;'>#PI3K#</a>, objectTitle=全球**每日1次口服PI3K/CK1抑制剂获FDA批准上市，治疗淋巴瘤, objectType=article, longId=206994, objectId=d418206994cd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d418206994cd, replyNumber=0, likeNumber=54, createdTime=2021-02-10, rootId=0, userName=ms1292405679162969, userId=7bb22500091, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d418206994cd, moduleTitle=全球**每日1次口服PI3K/CK1抑制剂获FDA批准上市，治疗淋巴瘤, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=d418206994cd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1333243, encodeId=530c133324349, content=<a href='/topic/show?id=ecfa1423117' target=_blank style='color:#2F92EE;'>#PI3K#</a>, objectTitle=Blood：CBL突变通过强化LYN与PIK3R1相互作用驱动PI3K/AKT信号, objectType=article, longId=205501, objectId=048d20550149, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=048d20550149, replyNumber=0, likeNumber=93, createdTime=2021-01-10, rootId=0, userName=ms1292405679162969, userId=7bb22500091, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=048d20550149, moduleTitle=Blood：CBL突变通过强化LYN与PIK3R1相互作用驱动PI3K/AKT信号, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=048d20550149)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1333242, encodeId=a9891333242c8, content=<a href='/topic/show?id=ecfa1423117' target=_blank style='color:#2F92EE;'>#PI3K#</a>, objectTitle=Blood：Umbralisib用于BTK或PI3Kδ抑制剂不耐受的CLL患者的疗效和耐受性, objectType=article, longId=204131, objectId=bf81204131cf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bf81204131cf, replyNumber=0, likeNumber=65, createdTime=2020-12-06, rootId=0, userName=ms1292405679162969, userId=7bb22500091, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bf81204131cf, moduleTitle=Blood：Umbralisib用于BTK或PI3Kδ抑制剂不耐受的CLL患者的疗效和耐受性, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=bf81204131cf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1333241, encodeId=1307133324146, content=<a href='/topic/show?id=ecfa1423117' target=_blank style='color:#2F92EE;'>#PI3K#</a>, objectTitle=Blood：Umbralisib治疗对不能耐受BTK和PI3Kδ抑制剂的CLL安全有效, objectType=article, longId=204085, objectId=2cde204085b1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2cde204085b1, replyNumber=0, likeNumber=0, createdTime=2020-12-05, rootId=0, userName=ms1292405679162969, userId=7bb22500091, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2cde204085b1, moduleTitle=Blood：Umbralisib治疗对不能耐受BTK和PI3Kδ抑制剂的CLL安全有效, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=2cde204085b1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1333240, encodeId=3e3513332402f, content=<a href='/topic/show?id=ecfa1423117' target=_blank style='color:#2F92EE;'>#PI3K#</a>, objectTitle=CD20单抗Ublituximab与PI3K抑制剂Umbralisib联合治疗慢性淋巴细胞白血病，获FDA快速通道指定, objectType=article, longId=202384, objectId=f40b202384ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f40b202384ce, replyNumber=0, likeNumber=111, createdTime=2020-10-24, rootId=0, userName=ms1292405679162969, userId=7bb22500091, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f40b202384ce, moduleTitle=CD20单抗Ublituximab与PI3K抑制剂Umbralisib联合治疗慢性淋巴细胞白血病，获FDA快速通道指定, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=f40b202384ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1333239, encodeId=4ee813332391b, content=<a href='/topic/show?id=ecfa1423117' target=_blank style='color:#2F92EE;'>#PI3K#</a>, objectTitle=Clin Cancer Res：多重免疫荧光鉴定前列腺癌单细胞水平的PI3K通路激活, objectType=article, longId=201678, objectId=299e2016e848, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=299e2016e848, replyNumber=0, likeNumber=64, createdTime=2020-10-06, rootId=0, userName=ms1292405679162969, userId=7bb22500091, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=299e2016e848, moduleTitle=Clin Cancer Res：多重免疫荧光鉴定前列腺癌单细胞水平的PI3K通路激活, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=299e2016e848)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1333238, encodeId=561e133323809, content=<a href='/topic/show?id=ecfa1423117' target=_blank style='color:#2F92EE;'>#PI3K#</a>, objectTitle=Cell Death Dis：LINC01559激活PI3K/AKT信号通路促进胃癌的发生发展, objectType=article, longId=200456, objectId=5d0e2004568a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5d0e2004568a, replyNumber=0, likeNumber=72, createdTime=2020-09-10, rootId=0, userName=ms1292405679162969, userId=7bb22500091, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5d0e2004568a, moduleTitle=Cell Death Dis：LINC01559激活PI3K/AKT信号通路促进胃癌的发生发展, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=5d0e2004568a)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] williamhill asia 话题小助手

PI3K

2020-05-29

williamhill asia 管理员 (审核中...)

前往app查看评论内容

#COPD# #PI3K# #NF-κB# #Nrf2# #肺部炎症# #定喘汤#

J Ethnopharmacol：结合网络药理学和药理学研究探讨定喘汤抗慢性阻塞性肺疾病的潜在机制

2024-03-04发表于上海

ms1292405679162969 (审核中...)

前往app查看评论内容

#PI3K#

Front Pharmacol：琥珀安神汤通过激活PI3K/AKT通路促进创伤性脑损伤大鼠的骨折愈合

2022-09-16

ms1292405679162969 (审核中...)

前往app查看评论内容

#PI3K#

FDA 关闭 PI3K 抑制剂单臂试验的大门，会给中国新药研发带来哪些启示？

2022-05-01

ms1292405679162969 (审核中...)

前往app查看评论内容

#PI3K#

Clin Cancer Res：首次人源性I期研究评估了PI3K/mTOR抑制剂GDC-0084在胶质瘤患者中的应用

2021-12-30

ms1292405679162969 (审核中...)

前往app查看评论内容

#PI3K#

PI3K/Akt信号通路在胃癌干细胞中的表达及意义

2021-11-22

ms1292405679162969 (审核中...)

前往app查看评论内容

#PI3K#

Br J Pharmacol:丁酸盐通过增强肠道屏障功能和FFA2介导的PI3K/AKT/mTOR信号通路改善糖尿病肾病骨骼肌萎缩

2021-10-17

ms1292405679162969 (审核中...)

前往app查看评论内容

#PI3K#

Clin Cancer Res：PI3K/mTORC1/2双重抑制剂Gedatolisib联合卡铂和紫杉醇治疗晚期实体肿瘤

2021-08-19

ms1292405679162969 (审核中...)

前往app查看评论内容

#PI3K#

Nat Rev Drug Discov：PI3K抑制剂即将迎来大爆发

2021-06-25

ms1292405679162969 (审核中...)

前往app查看评论内容

#PI3K#

Nat Commun：靶向PI3K/AKT的过度激活诱导慢性淋巴细胞白血病的细胞死亡

2021-06-15

ms1292405679162969 (审核中...)

前往app查看评论内容

#PI3K#

Clin Cancer Res：首次人源性I期研究评估了PI3K/mTOR抑制剂GDC-0084在胶质瘤患者中的应用

2021-04-15

ms1292405679162969 (审核中...)

前往app查看评论内容

#PI3K#

信达生物PI3Kδ抑制剂parsaclisib拟纳入突破性治疗品种

2021-03-26

ms1292405679162969 (审核中...)

前往app查看评论内容

#PI3K#

Br J Cancer：PI3K信号通路激活导致HER2阴性乳腺癌的eribulin耐药性的产生

2021-03-24

ms1292405679162969 (审核中...)

前往app查看评论内容

#PI3K#

J Clin Oncol：PI3Kδ/CK1ε双重抑制剂Umbralisib用于治疗复发性/难治性惰性淋巴瘤

2021-03-11

ms1292405679162969 (审核中...)

前往app查看评论内容

#PI3K#

全球**每日1次口服PI3K/CK1抑制剂获FDA批准上市，治疗淋巴瘤

2021-02-10

ms1292405679162969 (审核中...)

前往app查看评论内容

#PI3K#

Blood：CBL突变通过强化LYN与PIK3R1相互作用驱动PI3K/AKT信号

2021-01-10

ms1292405679162969 (审核中...)

前往app查看评论内容

#PI3K#

Blood：Umbralisib用于BTK或PI3Kδ抑制剂不耐受的CLL患者的疗效和耐受性

2020-12-06

ms1292405679162969 (审核中...)

前往app查看评论内容

#PI3K#

Blood：Umbralisib治疗对不能耐受BTK和PI3Kδ抑制剂的CLL安全有效

2020-12-05

ms1292405679162969 (审核中...)

前往app查看评论内容

#PI3K#

CD20单抗Ublituximab与PI3K抑制剂Umbralisib联合治疗慢性淋巴细胞白血病，获FDA快速通道指定

2020-10-24

ms1292405679162969 (审核中...)

前往app查看评论内容

#PI3K#

Clin Cancer Res：多重免疫荧光鉴定前列腺癌单细胞水平的PI3K通路激活

2020-10-06

ms1292405679162969 (审核中...)

前往app查看评论内容

#PI3K#

Cell Death Dis：LINC01559激活PI3K/AKT信号通路促进胃癌的发生发展

2020-09-10

科室
- - 订阅+
  - 更多科室
工具
服务